Village Caregiving reports that frontotemporal dementia is a progressive brain disease affecting behavior, speech, and memory ...

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the ...

This represents Alector's second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in ...

Advanced MRI detects early frontotemporal dementia microstructural damage, enabling earlier diagnosis and monitoring of disease progression.

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; ...

The immediate consequences of the disappointing result are a big reduction in workforce at South San Francisco-based Alector, ...

In the wake of Bruce Willis' diagnosis, Emma Heming has taken to social media to raise awareness about FTD, a type of dementia that affects behavior, personality, and language. Through her heartfelt ...

An experimental drug from Alector Inc. failed to slow the decline of patients with frontotemporal dementia in a late-stage ...

A research registry tracking data on a particular form of dementia will be created under a new law sponsored by state Sen.

Alector’s ambitions for a breakthrough in rare dementia have been upended after its lead drug latozinemab (AL001), partnered ...

In a significant move to enhance awareness and understanding of frontotemporal degeneration (FTD), New York has enacted a new law that will create a statewide registry dedicated to tracking this ...